		——————————————————————————————————————						Silect I Ox	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)					ATTY DOCKET NO. 11582-006-999 (129955-999006) APPLICANT Ly et al. FILING DATE			APPLICATION NO 10/585,429	
				NT			CONFIRMATION NO.: 4713		
(Osc several slicets if flecessary)									
							ART UNIT:	ART UNIT:	
					July 7, 2006		1621		
			U.S. PA	TENT DOCUM	ENTS				
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	

			FOREIG	N PATENT DOCUMEN	TS			
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLA	TION
							YES	NO
	B04	EP 1 170 594 A	01/09/02	European Union				
	B05	EP 1 413 306 A	04/28/04	European Union				
	B06	DE 42 39 440 A	06/09/93	Germany				
	B07	GB 1356834	06/19/74	United Kingdom				+
<u> </u>	B08	GB 2 262 096 A	06/09/03	United Kingdom				+

	OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)
C03	International Search Report of International Application No. PCT/EP2004/003910 having a Publication No. WO 04/096777
C04	Ly, T. W., et al, "Small-Molecule CRTH2 Antagonists for the Treatment of Allergic Inflammation: An Overview," Expert Opin. Investig. Drugs, 14(7): 769-773 (2005)
C05	Ordukhanyan, A. A., et al, Khimiko-Farmatsevticheskii Zhurnal, 13(9): 36-40 (1979) (Article in Russian) provided)
C06	Ordukhanyan, A. A., et al, Khimiko-Farmatsevticheskii Zhurnal, 13(9): 36-40 (1979) (English abstract)
C07	Ulven, T., et al, "Novel Selective Orally Active CRTH2 Antagonists for Allergic Inflammation Developed from In Silico Derived Hits," J. Med. Chem., 49:6638-6641 (2006)

EXAMINER	/Jeffrey Murray/	DATE CONSIDERED	09/21/2009
*EXAMINER: Initi	al if reference considered, whether or not ci	ation is in conformance with MPEP 609; Draw line the	hrough citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.